نتایج جستجو برای: deferasirox
تعداد نتایج: 613 فیلتر نتایج به سال:
Background: Deferasirox is an oral iron chelator widely used to treat iron overload in patients with transfusion-dependent β-thalassemia. This study investigated the prevalence of visual and auditory complications caused by deferasirox. Materials and Methods: This cross-sectional study included 156 patients aged less than 18 years with transfusion-dependent β-thalassemia and deferasirox iron...
ABSTACT Human hepatocellular carcinoma (HCC) is known to have a poor prognosis. Sorafenib, a molecular targeted drug, is most commonly used for HCC treatment. However, its effect on HCC is limited in clinical use and therefore new strategies regarding sorafenib treatment are required. Iron overload is known to be associated with progression of chronic hepatitis and increased risk of HCC. We pre...
UNLABELLED Hereditary hemochromatosis (HH) is characterized by increased intestinal iron absorption that may result in iron overload. Although phlebotomy is widely practiced, it is poorly tolerated or contraindicated in patients with anemias, severe heart disease, or poor venous access, and compliance can vary. The once-daily, oral iron chelator, deferasirox (Exjade) may provide an alternative ...
Objective: It has been shown that deferasirox can reduce blood and tissues lead content in animal models. In this study the effect of deferasirox alone or combined with glycine as an antioxidant was evaluated in chronic cadmium toxicosis in rat. Methods: Male wistar albino rats were exposed to 200 ppm cadmium in the drinking water for 3 weeks and treated thereafter with deferasirox (140 mg/kg),...
Abstract Background Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major. Combined therapy with deferiprone(DFP) and desferrioxamine (DFO)were suggested to be more effective than deferasirox(DFX) for removing heart iron. Deferasirox has recently been made available, but its long-term efficacy on cardiac function has not yet been established. Our study...
Objective: It has been shown that deferasirox can reduce blood and tissues lead content in animal models. In this study the effect of deferasirox alone or combined with glycine as an antioxidant was evaluated in chronic cadmium toxicosis in rat. Methods: Male wistar albino rats were exposed to 200 ppm cadmium in the drinking water for 3 weeks and treated thereafter with deferasirox (140 mg/kg),...
Objective: It has been shown that deferasirox can reduce blood and tissues lead content in animal models. In this study the effect of deferasirox alone or combined with glycine as an antioxidant was evaluated in chronic cadmium toxicosis in rat. Methods: Male wistar albino rats were exposed to 200 ppm cadmium in the drinking water for 3 weeks and treated thereafter with deferasirox (140 mg/kg),...
PROPOSAL The World Health Organization Model List of Essential Medicines and Model Formulary 2010 list deferoxamine (DFO) as the treatment of choice for both acute and chronic iron poisoning. The Model Formulary currently does not designate any orally administered agents for the chelation of iron. It is proposed that deferasirox be considered the oral chelator of choice in the treatment of chro...
Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید